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Abstract
Context: In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers,
including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for
therapeutic monitoring and as prognostic and predictive biomarkers. However, there is a lack of
consensus and standardisation regarding analyses, reporting, and integration of results into specific
clinical contexts. A consensus meeting on circulating biomarkers was held to address these topics.
Objective: To present a report of the consensus statement on circulating biomarkers in advanced PC.
Evidence acquisition: Four important areas of controversy in the ﬁeld of circulating biomarkers in PC
management were identiﬁed: known clinical utility of circulating biomarkers; unmet clinical needs for
circulating biomarkers in PC care; most pressing blood-based molecular assays required; and essential
steps for developing circulating biomarker assays. A panel of 18 international PC experts in the ﬁeld of
circulating biomarkers developed the programme and consensus questions. The panel voted publicly
but anonymously on 50 predeﬁned questions developed following a modiﬁed Delphi process.
Evidence synthesis: Voting was based solely on panellist opinions of the predeﬁned topics and
therefore not on a standard literature review or meta-analysis. The outcomes of the voting had
varying degrees of support, as reﬂected in thewording of this article and in the detailed voting results
provided in the Supplementary material.
Conclusions: The expert voting results presented can guide the future development of circulating
biomarkers for PC care. Notably, the consensus meeting highlighted the importance of reproducibil-
ity and variability studies, among other signiﬁcant areas in need of trials speciﬁcally designed to
address them.
Patient summary: A panel of international experts met to discuss and vote on the use of different
blood-based prostate cancer tests, and how they can be used to guide treatment and disease
monitoring to deliver more precise and better patient care.
© 2018 European Association of Urology. Published by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).y These authors contribute
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E U RO P E AN URO L OGY ONCO L OGY 1 ( 2 018 ) 151 – 15 91521. IntroductionThe urgent need for circulating biomarkers for the care of
advanced prostate cancer (PC) patients is well described,
but there is a lack of consensus regarding how these should
be discovered and developed, with little transformative
prospective trial data. Investigations focusing on the utility
of blood-based assays including plasma cell-free nucleic
acids (eg, cell free DNA [cfDNA]) and circulating tumour
cells [CTCs] have generated major interest and could
transform patient care. A consensus meeting was held to
address these issues and produce a statement on circulating
biomarkers in advanced PC, defined asmetastatic disease or
disease that recurred after local treatment. The panel
comprised 18 physicians and scientists from nine countries
selected on the basis of their academic track record and
involvement in clinical or translational research in the field
of advanced PC, with expertise in the clinical qualification of
biomarkers. None of the invited experts declined the
invitation to participate. Before this meeting, the panel
identified four areas of controversy for discussion:1. Current utility of circulating biomarkers.
2. Unmet clinical needs for circulating biomarkers in PC
care.
3. Most pressing blood-based molecular assays required.
4. Essential steps for development of circulating biomarker
assays.
2. Evidence acquisition
A modified Delphi process was used for consensus
development, following procedures described by Gillessen
et al. [1]. The meeting comprised state-of-the-art lectures,
presentations, and debates by panellists before voting.
Following this, 50 questions that were previously agreed on
were presentedwith options for answers inmultiple-choice
format. Panellists voted anonymously, with results dis-
played to all attendees immediately. For all questions,
responses were based on idealised assumptions that all
diagnostic procedures (including expertise in interpretation
and application) mentioned were readily available. Impor-
tantly, in an effort to address questions from an evidence-
based and clinical utility perspective, panellists were
specifically instructed not to consider cost, reimbursement,
and access in their deliberations, although clearly these are
critical factors in decision-making.
We acknowledge that the results reflect the opinions of a
small chosen panel of experts on predefined topics, and
therefore are not based on a standard literature review or
meta-analysis. The results presented are intended to serve
only as a guide to clinicians, researchers, and industry
partners. The option “unqualified to answer” (short form:
“unqualified”) should have been chosen if a panellist lacked
experience for a specific question, and the “abstain” option
if a panellist felt unable to vote for any reason. Detailed
voting records for all questions are provided in the
Supplementary material. The denominator was based on
the number of panel members voting on the particularquestion, excluding those who voted “unqualified” or
“abstain”. Consensus was declared if 75% of the panellists
chose the same option and did not abstain or vote
“unqualified” [2]. Throughout, the percentage of voting
panellists giving a particular response is reported, followed
by absolute numbers. All panellists contributed to designing
the questions, editing the manuscript, and approving this
final document. Importantly, this process was uniquely able
to highlight areas of disagreement and identify priorities for
future clinical research for which additional data acquisi-
tion is warranted.
3. Evidence synthesis
3.1. Current utility of circulating biomarkers
3.1.1. CTC assays
Multiple assays have been described for CTC evaluation; the
CellSearch system is the only one with regulatory clearance
for monitoring PC and has not been improved since its
introduction in 2008. CTC number is robustly associated
with poor outcome, with declining counts indicating
response to therapy [3,4]. Accurate assessment of the actual
number of CTCs is especially important when assessing
therapy response, and prospective trials evaluating CTC
enumeration as response and surrogate biomarkers of
response in PC are ongoing. To eliminate inter- and intra-
operator bias, the open source ACCEPT software has been
developed, allowing automatic CTC enumeration [5].
For CTC testing/enumeration with any assay, 33% (6/18)
of the experts voted that testing was ready for use in daily
routine clinical practice, 61% (11/18) that current data
support testing in prospective trials, and 6% (1/18) that
clinical studies are required before prospective clinical
validation trials.
For CellSearch CTC counting specifically, 67% (12/18) of
the experts voted that testing was ready for use in daily
routine clinical practice, 22% (4/18) that current data
support testing in prospective trials, and 11% (2/18) that
clinical studies are required prior to prospective, clinical
validation trials.
Overall, most of the experts endorsed the utility of CTC
counts via CellSearch in clinical practice and trials (given
the available data and US Food and Drug Administration
[FDA] clearance); however, consensus was not reached
regarding routine clinical use.
3.1.2. Alternative CTC detection
The successful development of the CellSearch system
prompted the study of alternative CTC detection platforms,
with >50 companies currently involved in developing and
marketing CTC-based liquid biopsy tools [6]. The use of
validated CTC detection methods that minimise false
positives and allow molecular analyses is mandated.
Limitations in CTC detection have been acknowledged;
with several patients having undetectable CTCs despite
progressive disease, difficulties in capturing these rare
events in those that do, and possible subsequent size-
selection bias.
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that testing was ready for use in daily routine clinical
practice; 61% (11/18) voted that current data support testing
in prospective trials and 39% (7/18) that clinical studies are
required prior to prospective, clinical validation trials.
The experts voted, based on current knowledge, on the
most appropriate clinical situation for CTC testing if the
tests were readily available: 28% (5/18) voted for testing
before starting first-line PC treatment, 16.5% (3/18) for
testing before starting second-line or greater treatment,
39% (7/18) for testing before starting treatment for
advanced disease, and 16.5% (3/18) for no appropriate
clinical situation currently.
The experts voted on whether CTC assays are likely to
impact patient care by 2020, with 33% (6/18) voting yes, 33%
(6/18) likely, 28% (5/18) possibly, and 6% (1/18) no.
Overall, the experts indicated an urgent need for clinical
trials to validate and qualify CTC-based genomic biomarkers.
3.1.3. AR-V7 expression in CTCs
mRNA transcripts for many androgen receptor (AR) splice
variants have been described and characterized [7]. AR
splice variant-7 (AR-V7) has received the most attention [8]
because it is:1. Most abundant, making robust detection more feasible;
2. Constitutively active and functionally relevant (may
mediate castration resistance);
3. Detectable by antibodies against a variant-specific 16–
amino acid sequence; and
4. Associated with increasing levels with the emergence of
castration resistance.
A blood-based AR-V7 test using the Adnagen CTC assay
has been described as being reproducible, with pretreat-
ment AR-V7 detection associated with poorer responses to
abiraterone/enzalutamide and poor outcome [9–11]. This
test has been implemented in a clinical testing laboratory
with Clinical Laboratory Improvement Amendments certi-
fication and has been used in a biomarker selection trial
[12,13]. A number of validation studies are still ongoing
[14,15], with the specific context of use yet to be defined. In
addition, cross-platform comparisons of various AR-V7 tests
have yet to be performed.
For AR-V7 testing, 6% (1/18) voted that testing was ready
for use in daily routine clinical practice, 72% (13/18) that
current data support testing in prospective trials, and 22%
(4/18) that clinical studies are required before prospective
clinical validation trials.
Regarding which AR-V7 test should be used in daily
routine clinical practice if only one test were funded, 31% (4/
13) of the experts voted for the EPIC AR-V7 CTC protein assay,
7.67% (1/13) for the Hopkins/Qiagen AR-V7 RT-PCR Adnagen
CTC assay, 7.67% (1/13) for a custom RT-PCR based CTC assay,
7.67% (1/13) for any/either of these tests, and 46% (6/13) for
the option that there is currently no appropriate assay.
Overall, the experts required prospective clinical trial
data to validate and qualify AR-V7 testing before this is used
clinically.3.1.4. cfDNA assays
cfDNA has prognostic and potentially predictive utility,
allowing the identification of tumour genomic aberrations.
Studies comparing cfDNA aberrations with matched con-
temporaneous biopsies indicate that somatic mutations
identified in biopsies are detectable in cfDNA. Furthermore,
cfDNA analyses can identify additional mutations not
represented in a biopsy, as cfDNA comprises genomic
material released from multiple metastases [16]. Copy
number profiles of matched liquid and solid biopsies are
also highly correlated, although detection of copy number
changes, particularly deletions, requires higher tumour
DNA fractions (>35%). Higher total cfDNA is associatedwith
poorer outcome and may be a biomarker of aggressive
disease or disease burden [17,18]; decreases in cfDNAduring
therapy are associated with response and better outcomes
[19,20]. Serial measurement of cfDNA levels and tumour
fractions may be useful for monitoring prognosis, disease
burden, and response to treatment.
For cfDNA analysis, 6% (1/17) of the experts voted that
testing was ready for use in daily routine clinical practice,
59% (10/17) that current data support testing in prospective
trials, and 35% (6/17) that clinical studies are required
before prospective clinical validation trials.
For quantitative analyses of cfDNA concentrations, none
of the experts voted that testing was ready for use in daily
routine clinical practice, 39% (7/18) voted that current data
support testing in prospective trials, and 61% (11/18) that
clinical studies are required before prospective clinical
validation trials.
Genomic alterations in AR including mutations, amplifi-
cation, and structural rearrangements are demonstrable in
cfDNA and can drive endocrine treatment resistance [17–
19,21]. Other aberrations detected in cfDNA include
alterations in DNA repair genes, TP53, and in PI3K pathway
genes [22]. Identifying thesemay assist in selecting patients
benefiting from novel treatment approaches such as PARP
inhibitors or platinum-based chemotherapy for DNA repair
defects [23] and AKT inhibition for aberrant PI3K pathways
[24]. Prospective studies testing the utility of cfDNA
profiling for treatment stratification are ongoing.
For genomic analyses of gene panels in cfDNA, 6% (1/18) of
the experts voted that testing was ready for use in daily
routine clinical practice, 72% (13/18) that current data support
testing inprospective trials, and 22% (4/18) that clinical studies
are required before prospective clinical validation trials.
The experts voted on the most appropriate clinical
situation, based on current knowledge, for cfDNA testing if
the tests were readily available: 6% (1/16) voted for testing
before starting treatment for metastatic PC, 6% (1/16) for
testing before starting first-line treatment, 38% (6/16) for
testing before starting second line PC treatment, 31% (5/
16) for before all of the three options while 19% (3/16) voted
for no appropriate clinical situation currently.
Overall, expert consensus was that cfDNA genomic
analyses should not yet be utilized in clinical practice
based on currently available data, with 94% (17/18) of the
panel requiring further prospective clinical trial validation
and/or qualification.
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Serial targeted next-generation sequencing of cfDNA has
identified AR somatic point mutations (2632A > G, p.
T878A; and 2105T > A, p.L702H) that develop on treatment
with abiraterone acetate and prednisolone [17]. These
mutations result in promiscuous AR activation by proges-
terone or prednisolone, respectively [18,25]. Detection of
cfDNA AR copy gain before starting enzalutamide and gain
of these mutations before abiraterone is associated with
lower response rates and shorter progression-free and
overall survival [19,26].
Besides ARmutations, overexpression, amplification, and
expression of splice variants, genomic structural rearrange-
ments (GSRs) in AR have been identified as potential
predictive biomarkers in the context of castration resistance.
GSRs are defined as the presence of at least one breakpoint in
the AR gene [26–28]. ARGSRs have been identified in tumour
and liquid biopsies frompatientswith advanced PC, but have
not been detected in localised androgen-dependent disease
[29]. Limitations and future challenges in detecting AR GSRs
in cfDNA include the presence of highly repetitive regions
within the AR gene that are difficult to sequence, and the
possibility of missing GSR events in these regions. The
clinical relevance and functional effects of different AR GSRs
have not yet been established.
For AR copy gain/mutations in cfDNA testing, none of the
experts voted that testing was ready for use in daily routine
clinical practice, 83% (15/18) that current data support testing
in prospective trials, and 17% (3/18) that clinical studies are
required before prospective clinical validation trials.
The experts voted on the most appropriate clinical
situation, based on current knowledge, for AR-V7/AR copy
gain/ARmutation testing if the tests were readily available:
18% (3/17) voted for testing before starting first-line PC
treatment, 29% (5/17) for testing before starting second-line
or greater PC treatment, 29% (5/17) for before all three
options, and 24% (4/17) for no appropriate clinical situation
currently.
The experts voted on whether cfDNA assays are likely to
impact patient care by 2020: 67% (12/18) voted yes, 17%
likely (3/18), 11% possibly (2/18), and 5% (1/18) no.
Overall, the expert consensus indicated that further
evaluation in prospective clinical trials is merited before AR
genomic aberration testing can be implemented in clinical
practice. Most of the expert panel voted for cfDNA
biomarkers impacting patient care by 2020.
3.1.6. MicroRNAs
MicroRNAs (MiRs) are 20–25-bp noncoding RNAs regulat-
ing gene expression through interaction with complemen-
tary binding sites of target mRNAs. MiR expression is
deregulated in tumours and MiRs are released into the
circulation. The correlation between MiR expression and
specific cancer types, combined with MiR stability in blood,
makes these important biomarkers for evaluation
[30,31]. Published studies indicate that high baseline levels
of some MiRs, perhaps most notably MiR-375, are
associated with poorer prognosis [32–34]. Although pro-
spective validation and qualification through clinical trialsare required to confirm these associations, MiRs show
promise as prognostic, predictive, and therapy-monitoring
biomarkers.
The experts voted on the clinical need for PC-focused
targeted MiR profiling: 81% (13/16) voted that this was of
low priority and 19% (3/16) that this was a high (relevant)
clinical need.
Overall, the experts recommended that more data on
MiR PC disease biology are needed to support the pursuit of
clinical circulating biomarker studies.
3.2. Unmet clinical needs for circulating biomarkers for
monitoring PC care
Clinical trials for men with PC require clinically meaningful
endpoints that are valid measures of response and survival
[35]. Many patients have bone-only disease, which poses
particular challenges to diseasemonitoring [36,37], and PSA
and symptoms commonly drive treatment-switch deci-
sions. The need for superior circulating biomarkers in this
setting is of paramount importance to better identify
patients not benefiting from treatment before worsening of
their clinical condition precludes the use of alternative,
potentially active agents. The development and validation
of surrogate biomarkers of survival can also improve the
identification of active agents in phase 2 trials and allow
alternative phase 3 trial endpoints to facilitate the approval
and incorporation of novel agents into daily clinical practice.
Regarding the clinical need for circulating response
biomarkers, 72% (13/18) of the experts voted for this as a
very high need (development urgently needed), 17% (3/18)
as a high/relevant clinical need, and 11% (2/18) as a low
clinical need.
Regarding the clinical situation for which the develop-
ment of circulating response biomarkers is most relevant,
100% (17/17) of the experts voted for metastatic PC.
Regarding the clinical need for circulating biomarkers as
surrogate endpoints for clinical trials, 72% (13/18) of the
experts voted for a very high need, 6% (1/18) for a high/
relevant clinical need, and 22% (4/18) for a low clinical need.
Regarding the clinical situation for which the develop-
ment of circulating biomarkers as surrogate endpoints for
clinical trials is most relevant, none of the experts voted for
population-based screening, 5.5% (1/18) voted for localised/
locally advanced PC, 5.5% (1/18) for recurrence after radical
treatment, and 89% (16/18) for metastatic PC.
Overall, there was expert consensus that there is a very
high or high need for circulating response and surrogate
endpoint biomarkers, with all the experts voting for these
being most relevant for metastatic PC.
3.3. Most pressing blood-based molecular assays required
There is an urgent unmet clinical need for biomarkers that
can predict treatment benefit and allow a precision
medicine approach to care. Predictive biomarkers measur-
able in the circulation in cfDNA or CTC were discussed
(Table 1). These included genes commonly aberrant in PC,
such as genes involved in DNA repair that are associated
Table 1 – Additional predictive biomarkers that may be measurable in the circulation either in ctDNA or CTCs.
Predictive
biomarker
Context of use Mechanism Therapies linked to
predictive biomarker
Novel strategic
approaches
AR variants (AR-V7)
in CTCs (EPIC AR-V7
protein, Qiagen/
Hopkins Adnatest RT-
PCR)
Second-line mCRPC
following
enzalutamide or
abiraterone failure
Lack of AR LBD and drug target
of abiraterone or enzalutamide
(ligand independent signalling)
Lack of beneﬁt with
abiraterone or
enzalutamide (requires
validation)
Not predictive of taxane
beneﬁt clinically
N-terminal or DNA-
binding domain AR
inhibitors, BRD4
inhibitors, novel
strategies
AR copy gain
(ampliﬁcation)
mCRPC High AR levels may lead to
altered splicing decisions,
activity despite low
testosterone levels
Possible lack of beneﬁt
with abiraterone or
enzalutamide (unclear,
requires validation)
Novel AR pathway
inhibitors
AR mutations (F876L,
T878A, H875Y,
L702H) in ctDNA,
biopsies, CTCs
mCRPC Agonistic mutations for anti-
androgens, glucocorticoids,
progesterone
May be associated with
resistance to bicalutamide,
enzalutamide, abiraterone/
prednisone
Novel AR pathway
inhibitors
3bHSD1 mutations,
N367T
mHSPC/CRPC Gain-of-function mutation
promoting DHT synthesis from
DHEA
Resistance to ADT, early
CRPC development
Early use of AR
pathway inhibition in
mHSPC
Homologous DNA
repair defects
(BRCA2, BRCA1,
FANCA, PALB2, ATM)
mCRPC Sensitivity to PARP inhibition
synthetic lethality
May be associated with
greater beneﬁt to PARP
inhibitors, platinum-
compounds
PARP inhibitors or
platinum-based
chemotherapy
DNA mismatch repair
defects (Lynch
syndrome genes)
mCRPC High mutational load,
neoantigen generation,
immune responsiveness and
inﬁltration, PDL-1 upregulation
PD-1 or PDL-1 inhibition
possibly based on small
trials in MMR deﬁcient
Requires prospective
validation of PD-1/
PDL-1 inhibition
PTEN loss, PI3K/AKT
pathway activation
mCRPC Activation of PI3K/AKT/mTOR
pathway
Possible beneﬁt to PI3K or
AKT inhibition, ideally in
combination with AR
inhibition given reciprocal
feedback of pathways
PI3K/AKT inhibition
with abiraterone or
enzalutamide
MAPK activation
(RAF1 mutations,
MEK activation)
mCRPC MAPK signalling, survival,
metastasis
MEK or BRAF inhibitors
potentially
Trametinib,
regorafenib, others
Intact RB, gain in
CDK4/6 or cyclin-D1
mCRPC Intact cell-cycle pathway
checkpoints
Susceptibility to CDK4/6
inhibitors
CDK4/6
inhibitors  AR-
directed therapies
Wnt pathway
alterations
mCRPC b-Catenin activation and Wnt
canonical or noncanonical
pathway activation
Wnt pathway inhibition
under study
Porcupine inhibition,
immunotherapy
ctDNA = circulating tumour DNA; CTCs = circulating tumour cells; AR = androgen receptor; PC = prostate cancer; mCRPC = metastatic PC; mHSPC = metastatic
hormone-sensitive PC; LBD = ligand-binding domain; DHT = dihydrogen-testosterone; DHEA = dehydroepiandrosterone; ADT = androgen deprivation therapy.
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PI3K/AKT pathway inhibition efficacy. These were consid-
ered promising, but with circulating assays needing further
development and validation.
The experts voted on a number of blood-basedmolecular
assays and the clinical need for their development, as
shown in Table 2.
Regarding the clinical need for predictive circulating
biomarkers, 94% (17/18) of the experts voted for a very high
need (development urgently needed), 6% (1/18) for a high/
relevant clinical need, and none for a low clinical need (not a
key priority for this purpose).
Regarding the clinical situation for which the develop-
ment of predictive circulating biomarkers is most relevant,
none of the experts voted for population-based screening
for PC, 11% (2/18) for localised/locally advanced PC, none for
recurrence after radical treatment, and 89% (16/18) for
metastatic PC.
Regarding the systemic therapy in greatest need of a
predictive circulating biomarker in menwith PC, 11% (2/18)
of the experts voted for abiraterone/enzalutamide, 11% (2/18) for PARP inhibition or platinum-based chemotherapy,
28% (5/18) for immunotherapy, and 50% (9/18) for all
systemic treatments.
Regarding the systemic therapy with the least need of a
predictive circulating biomarker in men with PC, 6% (1/17)
of the experts voted for abiraterone/enzalutamide, 18% (3/
17) for taxane chemotherapy, 35% (6/17) for radium-223,
and 41% (7/17) for none of the systemic treatments.
Regarding the clinical need for prognostic circulating
biomarkers, 17% (3/18) of the experts voted for a very high
need, 28% (5/18) for a high/relevant clinical need, and 55%
(10/18) for a low clinical need.
Regarding the clinical situation for which the develop-
ment of prognostic circulating biomarkers is most relevant,
none of the experts voted for population-based screening
for PC, 59% (10/17) for localised/locally advanced PC, 18% (3/
17) for recurrence after radical treatment, and 23% (4/17) for
metastatic PC.
The overwhelming expert consensus was that there is an
urgent clinical need for circulating predictive biomarkers
and that the greatest need is for metastatic PC.
Table 2 – Expert voting on the clinical need for predictive circulating biomarkers that may be present in circulating nucleic acids or CTCs
Test Votes on clinical need, % (n/N) a
Very high High Low
CTC phenotyping and genotyping 61% (11/18) 28 (5/18) 11 (2/18)
Androgen receptor variant assays 33% (6/18) 56 (10/18) 11 (2/18)
Neuroendocrine biomarker analyses 24 (4/17) 41 (7/17) 35 (6/17)
PTEN loss analyses 19 (3/16) 25 (4/16) 56 (9/16)
DNA repair defect analyses 94 (16/17) 6 (1/17) 0
RB1 loss 12 (2/16) 50 (8/16) 38 (6/16)
Mismatch repair/microsatellite instability signatures 71 (12/17) 23 (4/17) 6 (1/17)
Immunological biomarker studies (eg, PD-L1, PD-L2) 39 (7/18) 33 (6/18) 28 (5/18)
PC-focused targeted NGS gene panel 67 (12/18) 33 (6/18) 0
PC-focused targeted microRNA proﬁling 0 19 (3/16) 81 (13/16)
CTC = circulating tumour cell; PC = prostate cancer; NGS = next-generation sequencing.
a Very high = high clinical need, development urgently needed; high = relevant clinical need; low = not a key priority for this purpose.
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assays
Biomarker development consists of two separate compo-
nents: analytical and clinical validation [38]. Analytic
validation establishes assay reproducibility and estimates
both error and utility in the clinical setting [39]. Many
variables can impact analytical validation of an assay. Initial
biomarker studiesmust establish themethodologywith the
best reproducibility and precision, including sample han-
dling, storage, and processing; evaluation of technical and
biological replicates; key quality control measures includ-
ing high and low limits of detection; intraobserver and
interobserver reproducibility; and the availability of ade-
quate controls [40]. After analytical validity has been
established, clinical qualification involves evaluation of
biomarker utility through clinical studies, frequently in a
multistep fashion involving multiple consecutive studies or
a single study with different stages to determine biomarker
fitness to impact a medical decision in a specific context of
use [41]. Each of the FDA-established biomarker contexts
(prognostic, predictive, response-indicator, efficacy-re-
sponse [surrogate]) requires adequately designed and
powered studies to establish clinical validity. In addition
to demonstrating clinical validation in a context, it is also
important to address the clinical utility of a biomarker by
establishing whether use of the biomarker result informs a
medical decision and improves patient outcomes.
The panel voted on what it considered to be critically
important steps in the development of circulating biomark-
ers for PC:- Regarding the need for healthy volunteer data in
circulating biomarker validation, 65% (11/17) of the
experts voted for very high, 29% (5/17) for high, and 6%
(1/17) for low importance.- Regarding reproducibility studies, the experts voted
unanimously (100%, 17/17) for very high importance.- Regarding variability studies, 94% (15/16) of the experts
voted for very high importance and 6% (1/16) for high
importance.- Regarding comparison of different platforms, 44% (7/16)
of the experts voted for very high importance, 31% (5/16)for high importance, 19% (3/16) for low importance, and
6% (1/16) for not important.- Regarding qualification involving prospective clinical
trials, 82% (14/17) voted for very high importance and
18% (3/17) for high importance.
The experts voted whether a tumour biopsy–based assay
is preferable to a blood-based assay when both are feasible:
29% (5/17) voted yes while 71% (12/17) voted no.
Regarding the clinical need for circulating biomarkers for
diagnostic purposes, 44% (8/18) of the experts voted for a
very high need (development urgently needed), 28% (5/18)
for a high/relevant clinical need, and 28% (5/18) voted for a
low clinical need.
Regarding the clinical situation for which the develop-
ment of circulating biomarkers for diagnostic purposes is
most relevant, 50% (9/18) of the experts voted for
population-based PC screening, 11% (2/18) for localised/
locally advanced PC, 6% (1/18) for recurrence after radical
treatment, and 33% (6/18) for metastatic PC.
Regarding the clinical setting with the greatest utility for
a circulating biomarker of DNA homologous repair defi-
ciency, 6% (1/17) voted for localized disease, 47% (8/17) for
diagnosis of metastatic disease, 23% (4/17) for diagnosis of
metastatic castration-resistant disease, 6% (1/17) for PC
following progression on abiraterone/enzalutamide, and
18% (3/17) for PC following progression on all proven
therapies.
The experts also voted on circulating biomarker tests in
specific clinical situations and had to choose the best
performing assay (if all tests were available):- For menwith high-risk localised/locally advanced PC, 34%
(5/17) of the experts voted for cfDNA quantification and
sequencing, 13% (2/17) for CTC enumeration, and 53% (8/
17) for none of the tests.- For men with rising PSA after radical local treatment
(biochemical recurrence), 12% (2/17) of the experts voted
for cfDNA quantification and sequencing, 6% (1/17) for
CTC enumeration, and 82% (14/17) for none of the tests.- For men with newly diagnosed metastatic disease, 65%
(11/17) of the experts voted for cfDNA quantification and
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17) for none of the tests.- For men with metastatic PC, 67% (12/18) of the experts
voted for cfDNAquantification and sequencing, 22% (4/18)
for CTC enumeration, 5.5% (1/18) for AR-V7 testing, and
5.5% (1/18) for none of the tests.
Overall, there was expert consensus that reproducibility
(same sample and time point) and variability (different
samples and different time points) studies, healthy volun-
teer analyses as negative controls, and prospective clinical
trials are necessary to analytically validate circulating
biomarkers. Consensus was not reached on the need for
comparing different biomarker platforms. Surprisingly, the
majority of the panel preferred a liquid biopsy to a tumour
biopsy, with cfDNA being the preferred single test for the
majority, although consensus was not reached.
3.5. Counting the costs
Treatment of PC places a huge financial burden on health
systems [38]. Liquid biopsies can play a pivotal role in
limiting these costs, decreasing the administration of
ineffective drugs via earlier discontinuation by using
response biomarkers and identifying cancers unlikely to
respond to expensive anticancer drugs. The health eco-
nomic benefits of liquid biopsies must now be ascertained
in prospective clinical trials focusing not only on single
biomarker assays but also on the potential of more
advanced multiplex and multipurpose assays.
With regard to health economic analyses, 65% (11/17) of
the experts voted that this was of very high importance, 29%
(5/17) of high importance, and 6% (1/17) of low importance.
The overwhelming consensus of this expert panel was
that health economic analyses are of very high or high
importance in blood-based biomarker clinical trials.
4. Conclusions
PC has some of the highest cfDNA and CTC levels of all solid
tumours, allowing serial tumour genomic analyses during
treatment. This could transform clinical care of PC, as this is
a noninvasive and practical approach to selecting and
monitoring treatment, and elucidating drug resistance and
clonal evolution.
Overall, this meeting highlighted the urgent need for
prospective, bespoke, clinical trials to clinically qualify
circulating biomarkers for PC to deliver better and more
precise patient care. This paper summarises the current
knowledge on circulating biomarkers as guidance for future
assay and research/clinical protocol development, since
none of these tests are widely available or reimbursed in
clinical practice. Many questions are still unanswered in the
field of biomarker development, and the voting results of
the panel reflect the great need for circulating biomarkers
(mainly for prediction of treatment response and as
surrogate endpoints), while also highlighting the lack of
data, validation studies, and regulatory approval for the
majority of the tests discussed.The consensus of this expert panel was that such assays
are highly likely to impact patient care in the near-term,
with most experts (67%) recommending the use of
CellSearch CTC counts for clinical care. Expert consensus
indicated that prospective clinical trials to validate circu-
lating biomarkers are of paramount importance, with the
highest need being for predictive biomarkers for metastatic
PC. Metastatic PC was also established as the setting for
which circulating biomarkers are required as response
biomarkers and surrogate endpoints. Expert consensus was
also reached on the importance of variability and reproduc-
ibility studies in biomarker validation. Figure 1 demon-
strates the varying opinions on the current utility of the
biomarkers discussed.
Identification, analytical validation, and prioritisation of
circulating biomarkers intended to guide patient care
represent a major endeavour that must follow strict
experimental rules, being as complex and costly as drug
development. This should only be attempted by qualified
investigators, with biomarker integration into prospective
clinical trials requiring teams of highly trained and
experienced experts. With few exceptions, corporate
sponsors are often reluctant to fund biomarker develop-
ment; obtaining traditional grants for such work is also
frequently outside usual hypothesis-driven grant proposals,
making evidence development difficult. A solution to this
conundrum is for physicians and regulatory agencies to
reject clinical trials lacking biomarkers for patient selection
and/or treatment response. Industry partners, government
agencies, and investigators must understand that “all
comers” clinical trials for PC should only be performed if
they incorporate tissue and blood collection and adequate
patient consent to the qualification of predictive or
response biomarkers. Experts must lobby traditional
funders and regulatory agencies to support these endea-
vours, with co-ordinated efforts needed. The outcomes of
this expert consensus can help guide the development of
circulating biomarkers for PC care, identifying key areas for
prioritisation.
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